Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data Sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Drug discovery outsourcing services industry 3600 synopsis, 2018 – 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Service type trends
2.1.4 Drug type trends
2.1.5 Disease model trends
2.1.6 Therapeutic area trends
Chapter 3 Drug Discovery Outsourcing Services Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing prevalence of chronic diseases globally
3.2.1.2 Increasing demand for outsourcing novel drugs and therapeutics
3.2.1.3 Increasing R&D expenditure by pharmaceutical and biotechnology companies
3.2.1.4 Increasing technological advancements in drug discovery
3.2.2 Industry pitfalls & challenges
3.2.2.1 Intellectual property concerns
3.3 Growth potential analysis
3.3.1 By service type
3.3.2 By drug type
3.3.3 By disease model
3.3.4 By therapeutic area
3.4 COVID- 19 impact analysis
3.5 Regulatory landscape
3.5.1 U.S.
3.5.2 Europe
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.1.1 Pharmaceutical Product Development (Thermo Fisher Scientific, Inc.)
4.1.2 Laboratory Corporation of America Holdings (Covance Inc.)
4.1.3 IQVIA (Quintiles IMS Holdings, Inc.)
4.1.4 Eurofins Scientific
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players, 2022
4.4 Competitive positioning matrix, 2022
4.5 Strategy dashboard, 2022
Chapter 5 Drug Discovery Outsourcing Services Market, By Service Type, 2018 - 2032 (USD Million)
5.1 Key trends, by service type
5.2 Chemistry services
5.3 Biological services
Chapter 6 Drug Discovery Outsourcing Services Market, By Drug Type, 2018 - 2032 (USD Million)
6.1 Key trends, by drug type
6.2 Small-molecule drugs
6.3 Large-molecule drugs
Chapter 7 Drug Discovery Outsourcing Services Market, By Disease Model, 2018 - 2032 (USD Million)
7.1 Key trends, by disease model
7.2 In vitro models
7.3 Animal models
7.4 Cellular models
7.5 Other disease models
Chapter 8 Drug Discovery Outsourcing Services Market, By Therapeutic Area, 2018 - 2032 (USD Million)
8.1 Key trends, by therapeutic area
8.2 Diabetes
8.3 Neurology
8.4 Oncology
8.5 Infectious diseases
8.6 Other therapeutic areas
Chapter 9 Drug Discovery Outsourcing Services Market, By Region, 2018 - 2032 (USD Million)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East & Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East & Africa
Chapter 10 Company Profiles
10.1 Charles River Laboratories International, Inc.
10.2 IQVIA (Quintiles IMS Holdings, Inc.)
10.3 Laboratory Corporation of America Holdings (Covance Inc.)
10.4 Pharmaceutical Product Development (Thermo Fisher Scientific, Inc.)
10.5 WuXi AppTec
10.6 Eurofins Scientific
10.7 GenScript ProBio (Genscript Biotech Corporation)
10.8 Aragen Life Sciences Ltd.
10.9 Syngene International Limited
10.10 Aurigene Pharmaceutical Services Ltd.
10.11 Pharmaron
10.12 Shanghai ChemPartner
10.13 Jubilant Biosys Ltd (Jubilant Pharmova Limited)
